Show simple item record

dc.contributor.authorDunn, Jeffrey
dc.contributor.authorWatson, Maggie
dc.contributor.authorAitken, Joanne
dc.contributor.authorHyde, Melissa
dc.date.accessioned2018-11-01T00:08:50Z
dc.date.available2018-11-01T00:08:50Z
dc.date.issued2016
dc.identifier.issn1057-9249en_US
dc.identifier.doi10.1002/pon.4290en_US
dc.identifier.urihttp://hdl.handle.net/10072/100640
dc.description.abstractBackground New advanced melanoma therapies are associated with improved survival; however, quality of survivorship, particularly psychosocial outcomes, for patients overall and those treated with newer therapies is unclear. Objective Synthesize qualitative and quantitative evidence about psychosocial outcomes for advanced (stage III/IV) melanoma patients. Methods Five databases were searched (01/01/1980 to 31/01/2016). Inclusion criteria were as follows: advanced melanoma patients or sub‐group analysis; assessed psychosocial outcomes; and English language. Results Fifty‐two studies met review criteria (4 qualitative, 48 quantitative). Trials comprise mostly medical not psychosocial interventions, with psychosocial outcomes assessed within broader quality of life measures. Patients receiving chemotherapy or IFN‐alpha showed decreased emotional and social function and increased distress. Five trials of newer therapies appeared to show improvements in emotional and social function. Descriptive studies suggest that patients with advanced, versus localized disease, had decreased emotional and social function and increased distress. Contributors to distress were largely unexplored, and no clear framework described coping/adjustment trajectories. Patients with advanced versus localized disease had more supportive care needs, particularly amount, quality, and timing of melanoma‐ related information, communication with and emotional support from clinicians. Limitations included: lack of theoretical underpinnings guiding study design; inconsistent measurement approaches; small sample sizes; non‐representative sampling; and cross‐sectional design. Conclusions Quality trial evidence is needed to clarify the impact of treatment innovations for advanced melanoma on patients’ psychosocial well‐being. Survivorship research and subsequent translation of that knowledge into programs and services currently lags behind gains in the medical treatment of advanced melanoma, a troubling circumstance that requires immediate and focused attention.en_US
dc.description.peerreviewedYesen_US
dc.languageEnglishen_US
dc.publisherJohn Wiley & Sonsen_US
dc.relation.ispartofpagefrom1en_US
dc.relation.ispartofpageto10en_US
dc.relation.ispartofjournalPsycho-Oncologyen_US
dc.subject.fieldofresearchOncology and Carcinogenesis not elsewhere classifieden_US
dc.subject.fieldofresearchcode111299en_US
dc.titleSystematic Review of Psychosocial Outcomes for Patients with Advanced Melanomaen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.facultyGriffith Health, School of Public Healthen_US
gro.description.notepublicThis publication has been entered into Griffith Research Online as an Advanced Online Version.en_US
gro.hasfulltextNo Full Text


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record